

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/002624

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/66 A61K31/505 A61K31/506 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99/02166 A (ANGIOGENE PHARM LTD ; DOUGHERTY GRAEME (GB)) 21 January 1999 (1999-01-21) cited in the application page 12, line 17 - page 13, line 7; example 1	1-26
Y	BLEIBERG H: "CONTINUING THE FIGHT AGAINST ADVANCED COLORECTAL CANCER: NEW AND FUTURE TREATMENT OPTIONS" ANTI-CANCER DRUGS, RAPID COMMUNICATIONS, OXFORD, GB, vol. 9, no. 1, January 1998 (1998-01), pages 18-28, XP000882025 ISSN: 0959-4973 page 19, column 1, lines 43-46 page 20, line 13 -/-	1-26

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

23 September 2004

Date of mailing of the international search report

26/11/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2260 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Allnutt, S

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/002624

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/74368 A (ANGIOGENE PHARM LTD ; DAVIS PETER DAVID (GB); DOUGHERTY GRAEME (US)) 11 October 2001 (2001-10-11) claim 1	1-26
A	SIEMANN D W ET AL: "TARGETING TUMOR BLOOD VESSELS: AN ADJUVANT STRATEGY FOR RADIATION THERAPY" RADIOTHERAPY AND ONCOLOGY, AMSTERDAM, NL, vol. 57, no. 1, 1 October 2000 (2000-10-01), pages 5-12, XPO01007731 page 7, column 1, line 8 page 9, column 1, lines 30-33	1-26

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2004/002624

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18-26
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 18-26 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

...T/GB2004/002624

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9902166	A	21-01-1999	
		AU 741213 B2	29-11-2001
		AU 8231198 A	08-02-1999
		BR 9810681 A	15-08-2000
		CA 2292549 A1	21-01-1999
		CN 1262624 T	09-08-2000
		EP 1001785 A1	24-05-2000
		WO 9902166 A1	21-01-1999
		HU 0002493 A2	28-08-2001
		ID 25483 A	05-10-2000
		JP 3455549 B2	14-10-2003
		JP 2001515516 T	18-09-2001
		NO 20000077 A	07-01-2000
		NZ 501341 A	31-08-2001
		PL 337926 A1	11-09-2000
		SK 132000 A3	11-12-2000
		TR 9903149 T2	21-09-2000
		US 6423753 B1	23-07-2002
WO 0174368	A	11-10-2001	
		AU 4258101 A	15-10-2001
		AU 4258601 A	15-10-2001
		BR 0109671 A	04-02-2003
		BR 0109672 A	04-02-2003
		CA 2402078 A1	11-10-2001
		CA 2402539 A1	11-10-2001
		CN 1430515 T	16-07-2003
		CN 1422157 T	04-06-2003
		CZ 20023228 A3	15-01-2003
		CZ 20023231 A3	15-01-2003
		EE 200200549 A	16-02-2004
		EE 200200565 A	15-06-2004
		EP 1272199 A1	08-01-2003
		EP 1272200 A1	08-01-2003
		WO 0174368 A1	11-10-2001
		WO 0174369 A1	11-10-2001
		HU 0300290 A2	28-06-2003
		HU 0300576 A2	28-07-2003
		JP 2003528920 T	30-09-2003
		JP 2003528921 T	30-09-2003
		NO 20024646 A	15-10-2002
		NO 20024683 A	15-10-2002
		PL 357282 A1	26-07-2004
		SK 13902002 A3	02-05-2003
		SK 13912002 A3	02-05-2003
		US 2003055024 A1	20-03-2003
		US 2003166617 A1	04-09-2003
		ZA 200207108 A	04-12-2003
		ZA 200207114 A	04-02-2004